首页> 外文期刊>Clinical oncology >An isotoxic planning comparison study for stage II-III non-small cell lung cancer: Is intensity-modulated radiotherapy the answer?
【24h】

An isotoxic planning comparison study for stage II-III non-small cell lung cancer: Is intensity-modulated radiotherapy the answer?

机译:II-III期非小细胞肺癌的等毒规划比较研究:调强放射疗法是否是答案?

获取原文
获取原文并翻译 | 示例
       

摘要

Aims: Recent clinical series suggest that treating patients with isotoxic twice-daily radiotherapy may be beneficial. This dosimetric planning study compared the use of intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DRT) to deliver isotoxic treatment for non-small cell lung cancer (NSCLC) patients. Materials and methods: Twenty patients with stage II/III NSCLC were selected. A dose-escalated plan was produced retrospectively for each using three different methods: (i) three to five beams 3DRT; (ii) seven beams inverse-planned conformal radiotherapy; (iii) seven beams IMRT. The starting point for dose escalation was 55.8Gy in 1.8Gy per fraction twice-daily. The number of fractions was then increased until one or more organ at risk tolerance dose was exceeded or a maximum dose of 79.2Gy was reached. Results: The median escalated doses were 70.2, 66.6 and 64.8Gy for IMRT, 3DRT and inverse-planned conformal radiotherapy, respectively. IMRT allowed a significant dose increase in comparison with the other two methods (P0.05), whereas no significant difference was found between 3DRT and inverse-planned conformal radiotherapy. IMRT was more successful at escalating dose in patients where the brachial plexus and spinal canal were close to the planning target volume. IMRT did not allow the escalation of dose beyond 70.2Gy (82.8Gy BED10, 69Gy EQD2) due to the proximity of disease to the great vessels and the proximal bronchial tree. Conclusions: IMRT allows increased dose escalation compared with conformal radiotherapy. However, there is limited opportunity to escalate the prescription dose beyond 70.2Gy twice-daily in disease close to the central mediastinal structures.
机译:目的:最近的临床研究表明,每天两次同等放疗的患者可能是有益的。这项剂量规划研究比较了使用调强放射疗法(IMRT)和三维适形放射疗法(3DRT)为非小细胞肺癌(NSCLC)患者提供等毒性治疗。材料和方法:选择20例II / III期NSCLC患者。使用三种不同的方法分别为每种剂量制定了剂量递增计划:(i)3至5束3DRT; (ii)七束反向计划的保形放射疗法; (iii)七光束IMRT。剂量递增的起点是每天两次每次1.8Gy中的55.8Gy。然后增加分数的数量,直到超过一个或多个处于风险耐受剂量的器官或达到最大剂量79.2Gy。结果:IMRT,3DRT和逆计划适形放疗的中位递增剂量分别为70.2、66.6和64.8Gy。与其他两种方法相比,IMRT可使剂量显着增加(P <0.05),而3DRT与逆计划保形放射治疗之间未发现显着差异。在臂丛神经和椎管接近计划目标量的患者中,IMRT在提高剂量方面更为成功。由于疾病靠近大血管和近端支气管树,IMRT不允许剂量增加至超过70.2Gy(82.8Gy BED10、69Gy EQD2)。结论:与适形放疗相比,IMRT可使剂量增加。然而,在靠近中央纵隔结构的疾病中,将处方剂量提高到每天两次超过70.2Gy的机会有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号